Tango Therapeutics, Inc.
TNGX
$25.60
-$0.05-0.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 10.93% | 4.46% | |||
| Gross Profit | -10.93% | -4.46% | |||
| SG&A Expenses | 48.25% | 56.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.59% | 16.49% | |||
| Operating Income | -22.59% | -16.49% | |||
| Income Before Tax | -21.59% | -17.29% | |||
| Income Tax Expenses | 0.00% | 101.82% | |||
| Earnings from Continuing Operations | -21.59% | -17.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.59% | -17.46% | |||
| EBIT | -22.59% | -16.49% | |||
| EBITDA | -22.88% | -16.72% | |||
| EPS Basic | -16.47% | -7.64% | |||
| Normalized Basic EPS | -13.69% | -15.87% | |||
| EPS Diluted | -16.47% | -7.64% | |||
| Normalized Diluted EPS | -13.69% | -15.87% | |||
| Average Basic Shares Outstanding | 4.39% | 9.11% | |||
| Average Diluted Shares Outstanding | 4.39% | 9.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||